tetrandrine has been researched along with Cancer of Prostate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Q; Koul, HK; Koul, S; Shishodia, G | 1 |
| Chaudhary, P; Vishwanatha, JK | 1 |
| He, W; Kou, B; Liu, W; Wang, H; Xu, S; Yan, Y; Zhang, Y; Zheng, J | 1 |
3 other study(ies) available for tetrandrine and Cancer of Prostate
| Article | Year |
|---|---|
Tetrandrine (TET) Induces Death Receptors Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis.
Topics: Apoptosis; Benzylisoquinolines; Biobehavioral Sciences; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA Interference; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand | 2018 |
c-Jun NH2-terminal kinase-induced proteasomal degradation of c-FLIPL/S and Bcl2 sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzylisoquinolines; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Male; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Proto-Oncogene Proteins c-bcl-2 | 2014 |
Tetrandrine suppresses metastatic phenotype of prostate cancer cells by regulating Akt/mTOR/MMP-9 signaling pathway.
Topics: Antineoplastic Agents; Benzylisoquinolines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Male; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2016 |